GlassScriptPhysician profile
Alan B Goldsobel
NPI 1063528321
$66,438.00
in general payments reported to CMS, 2019-2025
38 companies · $3,936 in 2025
The $3,936 reported for 2025 was more than what 81% of Allergy & Immunology providers received nationally (typical 2025 total: $1,138).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $20K · 2020: $6,621 · 2021: $18K · 2022: $12K · 2023: $2,931 · 2024: $2,119 · 2025: $3,936.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,169 · Travel and Lodging: $2,765 · Consulting Fee: $1,513 · Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $1,300 · Education: $239.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,169.33 |
| Travel and Lodging | $2,765.18 |
| Consulting Fee | $1,512.50 |
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $1,300.00 |
| Education | $238.52 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Glaxosmithkline, LLC. | $29,958.16 | 2019-2025 | Nucala, Trelegy Ellipta |
| Optinose US, INC. | $17,121.27 | 2019-2022 | |
| Merck Sharp & Dohme LLC | $6,595.62 | 2019-2023 | |
| Astrazeneca Pharmaceuticals LP | $5,083.13 | 2019-2025 | Fasenra, Tezspire, Airsupra |
| Takeda Pharmaceuticals U.S.A., INC. | $1,559.06 | 2020-2024 | |
| Regeneron Healthcare Solutions, INC. | $1,398.52 | 2019-2024 | Dupixent |
| Octapharma USA, INC. | $1,207.93 | 2019-2025 | Cutaquig |
| Csl Behring | $617.00 | 2021-2025 | Hizentra, Haegarda, Andembry |
| Genzyme Corporation | $552.88 | 2019-2025 | |
| Genentech USA, INC. | $225.41 | 2019-2024 | Xolair |
| Teva Pharmaceuticals USA, INC. | $192.20 | 2019-2025 | Albuterol Sulfate |
| Alk-Abello, INC | $191.65 | 2019-2023 | Odactra, Grastek |
| Novartis Pharmaceuticals Corporation | $183.06 | 2019-2022 | |
| Sanofi-Aventis U.S. LLC | $176.65 | 2020 | |
| Ars Pharmaceuticals Operations, INC. | $173.30 | 2025 | Neffy |
Show all 34 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Ionis Pharmaceuticals, INC. | $143.21 | 2025 | Dawnzera |
| Boehringer Ingelheim Pharmaceuticals, INC. | $133.04 | 2020-2022 | |
| Kaleo, INC. | $120.48 | 2019-2021 | |
| Pharming Healthcare, INC. | $118.91 | 2019-2025 | Ruconest |
| Pfizer INC. | $114.79 | 2019-2021 | |
| Grifols USA, LLC | $114.37 | 2020-2025 | Xembify |
| Amgen INC. | $66.77 | 2024-2025 | Actimmune, Tezspire |
| Regeneron Pharmaceuticals, INC. | $64.46 | 2019 | |
| Horizon Therapeutics Plc | $49.60 | 2019-2021 | |
| Blueprint Medicines Corporation | $41.69 | 2024 | Ayvakit |
| Covis Pharma Gmbh | $41.12 | 2019-2020 | |
| Galderma Laboratories, L.P. | $31.41 | 2025 | Nemluvio |
| Biocryst US Sales Co., LLC | $30.04 | 2025 | Orladeyo |
| Hikma Pharmaceuticals USA | $28.10 | 2022-2023 | Ryaltris |
| Circassia INC. | $25.13 | 2020 | |
| Hospira, INC. | $22.80 | 2023 | |
| Mylan Specialty L.P. | $22.22 | 2019 | |
| Philips North America LLC | $21.97 | 2019 | |
| Uswm, LLC | $12.05 | 2021 |
4 companies reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Alan Goldsobel listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.